Janux Therapeutics JANX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Janux Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's return on equity?
- Janux Therapeutics (JANX) reported return on equity of -11.7% in Q1 2026.
- How has Janux Therapeutics's return on equity changed year-over-year?
- Janux Therapeutics's return on equity decreased by 25.7% year-over-year, from -9.3% to -11.7%.
- What is the long-term trend for Janux Therapeutics's return on equity?
- Over 3 years (2022 to 2025), Janux Therapeutics's return on equity has grown at a -14.5% compound annual growth rate (CAGR), from -18.4% to -11.5%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.